Towards discovery of new leishmanicidal scaffolds able to inhibit Leishmania GSK-3

References

• Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet 2018;392:951–70.
   PubMed Web of Science ®Google Scholar
• Ponte-Sucre A, Gamarro F, Dujardin JC, et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl Trop Dis 2017;11:e0006052.
   PubMed Web of Science ®Google Scholar
• Alvar J, Arana B, Leishmaniasis, impact and therapeutic needs. In: Rivas L, Gil C, ed. Leishmaniasis, impact and therapeutic needs. Drug discovery for leishmaniasis. Croydon, UK: Royal Society of Chemistry; 2018.
   Google Scholar
• Kini SG, Garg V, Prasanna S, et al. Protein kinases as drug targets in human and animal diseases. Curr Enzyme Inhib 2017;13:99–106.
   Google Scholar
• Klaeger S, Heinzlmeir S, Wilhelm M, et al. The target landscape of clinical kinase drugs. Science 2017;358:eaan4368.
   PubMed Web of Science ®Google Scholar
• Bhullar KS, Lagarón NO, McGowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 2018;17:48.
   PubMed Web of Science ®Google Scholar
• Chico LK, Van Eldik LJ, Watterson DM. Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov 2009;8:892–909.
   PubMed Web of Science ®Google Scholar
• Merritt C, Silva LE, Tanner AL, et al. Kinases as druggable targets in trypanosomatid protozoan parasites. Chem Rev 2014;114:11280–304.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Schorey JS, Zhang CC, Tan X. Protein kinase inhibitors as potential antimicrobial drugs against tuberculosis, malaria and HIV. Curr Pharm Des 2017;23:4369–89.
   PubMed Web of Science ®Google Scholar
• Padwal MK, Sarma U, Sudan R, Saha B. Macrophage kinases in leishmaniasis. In: Doerig C, Späth G, Wiese M, ed. Macrophage kinases in leishmaniasis. Protein phosphorylation in parasites: novel targets for antiparasitic intervention. Weinheim, Germany: Wiley‐Blackwell; 2013.
   Google Scholar
• Moreira D, Rodrigues V, Abengozar M, et al. Leishmania infantum modulates host macrophage mitochondrial metabolism by hijacking the SIRT1-AMPK axis. PLoS Pathog 2015;11:e1004684.
   PubMed Web of Science ®Google Scholar
• Li Z, Hao Y, Wang L, et al. Genome-wide identification and comprehensive analyses of the kinomes in four pathogenic microsporidia species. PLoS ONE 2014;9:e115890.
   PubMed Web of Science ®Google Scholar
• Davis MI, Patrick SL, Blanding WM, et al. Identification of novel Plasmodium falciparum hexokinase inhibitors with antiparasitic activity. Antimicrob Agents Chemother 2016;60:6023–33.
   PubMed Web of Science ®Google Scholar
• Parsons M, Worthey EA, Ward PN, Mottram JC. Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. BMC Genomics 2005;6:127.
   PubMed Web of Science ®Google Scholar
• Genestra M, Cysne-Finkelstein L, Leon L. Protein kinase a activity is associated with metacyclogenesis in Leishmania amazonensis. Cell Biochem Funct 2004;22:315–20.
   PubMed Web of Science ®Google Scholar
• Chow C, Cloutier S, Dumas C, et al. Promastigote to amastigote differentiation of leishmania is markedly delayed in the absence of perk elF2alpha kinase-dependent eIF2alpha phosphorylation. Cell Microbiol 2011;13:1059–77.
   PubMed Web of Science ®Google Scholar
• Hassan P, Fergusson D, Grant KM, Mottram JC. The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. Mol Biochem Parasitol 2001;113:189–98.
   PubMed Web of Science ®Google Scholar
• Zylbersztejn AMB, De Morais CGV, Lima AKC, et al. Ck2 secreted by Leishmania braziliensis mediates macrophage association invasion: a comparative study between virulent and avirulent promastigotes. BioMed Res Int 2015;2015:1. ID 167323.
   Web of Science ®Google Scholar
• Abhishek K, Sardar AH, Das S, et al. Phosphorylation of translation initiation factor 2-alpha in Leishmania donovani under stress is necessary for parasite survival. Mol Cell Biol 2017;37:e00344–00316.
   PubMed Web of Science ®Google Scholar
• Wiese M. A mitogen-activated protein (MAP) kinase homologue of Leishmania mexicana is essential for parasite survival in the infected host. EMBO J 1998;17:2619–28.
   PubMed Web of Science ®Google Scholar
• Morales MA, Pescher P, Späth GF. Leishmania major MPK7 protein kinase activity inhibits intracellular growth of the pathogenic amastigote stage. Eukaryot Cell 2010;9:22–30.
   PubMedGoogle Scholar
• Garg M, Goyal N. MAPK1 of leishmania donovani modulates antimony susceptibility by downregulating P-glycoprotein efflux pumps. Antimicrob Agents Chemother 2015;59:3853–63.
   PubMed Web of Science ®Google Scholar
• Naula C, Parsons M, Mottram JC. Protein kinases as drug targets in trypanosomes and leishmania. Biochim Biophys Acta 2005;1754:151–9.
   PubMed Web of Science ®Google Scholar
• Bendjeddou LZ, Loaëc N, Villiers B, et al. Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor. Eur J Med Chem 2017;125:696–709.
   PubMed Web of Science ®Google Scholar
• Palmeri A, Gherardini PF, Tsigankov P, et al. Phostryp: a phosphorylation site predictor specific for parasitic protozoa of the family trypanosomatidae. BMC Genomics 2011;12:614.
   PubMed Web of Science ®Google Scholar
• Tirado-Duarte D, Marín-Villa M, Ochoa R, et al. The Akt-like kinase of Leishmania panamensis: as a new molecular target for drug discovery. Acta Trop 2018;177:171–8.
   PubMed Web of Science ®Google Scholar
• Rachidi N, Taly JF, Durieu E, et al. Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection. Antimicrob Agents Chemother 2014;58:1501–15.
   PubMed Web of Science ®Google Scholar
• Genestra M, Echevarria A, Cysne-Finkelstei L, Leon LL. Protein kinase a of Leishmania amazonensis as a potential target for methoxy-amidine. Arzneim-Forsch Drug Res 2001;51:920–3.
   PubMed Web of Science ®Google Scholar
• Conseil G, Perez-Victoria JM, Jault JM, et al. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. Biochemistry 2001;40:2564–71.
   PubMed Web of Science ®Google Scholar
• Alvarez N, Robledo S, Velez ID, et al. Inhibition of parasite protein kinase C by new antileishmanial imidazolidin-2-one compounds. J Enzyme Inhib Med Chem 2002;17:443–7.
   PubMed Web of Science ®Google Scholar
• Chhajer R, Bhattacharyya A, Didwania N, et al. Leishmania donovani aurora kinase: a promising therapeutic target against visceral leishmaniasis. Biochim Biophys Acta Gen Subj 2016;1860:1973–88.
   PubMed Web of Science ®Google Scholar
• Ojo KK, Gillespie JR, Riechers AJ, et al. Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother 2008;52:3710–7.
   PubMed Web of Science ®Google Scholar
• Xingi E, Smirlis D, Myrianthopoulos V, et al. 6-Br-5-methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: Exploitation of GSK-3 for treating leishmaniasis. Int J Parasitol 2009;39:1289–303.
   PubMed Web of Science ®Google Scholar
• Ojo KK, Arakaki TL, Napuli AJ, et al. Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3. Mol Biochem Parasitol 2011;176:98–108.
   PubMed Web of Science ®Google Scholar
• Woodgett JR, Cormier KW. Recent advances in understanding the cellular roles of GSK-3. F1000Res 2017;6:pii: F1000 Faculty Rev-1167.
   Google Scholar
• Efstathiou A, Gaboriaud-Kolar N, Smirlis D, et al. An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial glycogen synthase kinase-3 over leishmanial CDC2-related protein kinase 3. Parasites Vectors 2014;7:234.
   PubMed Web of Science ®Google Scholar
• Klamer G, Song E, Ko KH, et al. Using small molecule GSK3beta inhibitors to treat inflammation. Curr Med Chem 2010;17:2873–81.
   PubMed Web of Science ®Google Scholar
• Peña I, Pilar Manzano M, Cantizani J, et al. New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. Sci Rep 2015;5:8771.
   PubMed Web of Science ®Google Scholar
• Martinez A, Alonso M, Castro A, et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer’s disease. J Med Chem 2002;45:1292–9.
   PubMed Web of Science ®Google Scholar
• Conde S, Perez DI, Martinez A, et al. Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. J Med Chem 2003;46:4631–3.
   PubMed Web of Science ®Google Scholar
• Perez DI, Conde S, Perez C, et al. Thienylhalomethylketones: irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorg Med Chem 2009;17:6914–25.
   PubMed Web of Science ®Google Scholar
• Palomo V, Perez DI, Perez C, et al. 5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. J Med Chem 2012;55:1645–61.
   PubMed Web of Science ®Google Scholar
• Palomo V, Soteras I, Perez DI, et al. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. J Med Chem 2011;54:8461–70.
   PubMed Web of Science ®Google Scholar
• Palomo V, Perez DI, Roca C, et al. Subtly modulating glycogen synthase kinase 3 beta: allosteric inhibitor development and their potential for the treatment of chronic diseases. J Med Chem 2017;60:4983–5001.
   PubMed Web of Science ®Google Scholar
• Perez DI, Palomo V, Perez C, et al. Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. J Med Chem 2011;54:4042–56.
   PubMed Web of Science ®Google Scholar
• Perez-Domper P, Palomo V, Gradari S, et al. The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Neuropharmacology 2017;116:174–87.
   PubMed Web of Science ®Google Scholar
• Salado IG, Redondo M, Bello ML, et al. Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem 2014;57:2755–72.
   PubMed Web of Science ®Google Scholar
• Sebastian-Perez V, Roca C, Awale M, et al. Medicinal and biological chemistry (MBC) library: an efficient source of new hits. J Chem Inf Model 2017;57:2143–51.
   PubMed Web of Science ®Google Scholar
• The UniProt Consortium. Uniprot: the universal protein knowledgebase. Nucleic Acids Res 2017;45:D158–D169.
   PubMed Web of Science ®Google Scholar
• Sievers F, Wilm A, Dineen D, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 2011;7:539.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2015–4: Ligprep. New York (NY): Schrödinger, LLC; 2015.
   Google Scholar
• Jorgensen WL, Tirado-Rives J. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 1988;110:1657–66.
   PubMed Web of Science ®Google Scholar
• Schrödinger Suite 2015–4 including Protein Preparation Wizard, Epik, Impact, and Prime. New York (NY): Schrödinger LLC; 2015.
   Google Scholar
• Schrödinger Release 2015–4: Maestro. New York (NY): Schrödinger, LLC; 2015.
   Google Scholar
• Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639–62.
   Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. Autodock4 and autodocktools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91.
   PubMed Web of Science ®Google Scholar
• Sherman W, Day T, Jacobson MP, et al. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 2006;49:534–53.
   PubMed Web of Science ®Google Scholar
• Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006;49:6177–96.
   PubMed Web of Science ®Google Scholar
• Jacobson MP, Friesner RA, Xiang Z, Honig B. On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol 2002;320:597–608.
   PubMed Web of Science ®Google Scholar
• Mathuram TL, Reece LM, Cherian KM. GSK-3 inhibitors: a double-edged sword? – An update on tideglusib. Drug Res 2018;68:436–43.
   PubMed Web of Science ®Google Scholar
• Dominguez JM, Fuertes A, Orozco L, et al. Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem 2012;287:893–904.
   PubMed Web of Science ®Google Scholar
• Luque-Ortega JR, de la Torre BG, Hornillos V, et al. Defeating leishmania resistance to miltefosine (hexadecylphosphocholine) by peptide-mediated drug smuggling: a proof of mechanism for trypanosomatid chemotherapy. J Control Rel 2012;161:835–42.
   PubMed Web of Science ®Google Scholar
• Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779–815.
   PubMed Web of Science ®Google Scholar
• Bertrand JA, Thieffine S, Vulpetti A, et al. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. J Mol Biol 2003;333:393–407.
   PubMed Web of Science ®Google Scholar
• Hefnawy A, Cantizani J, Peña I, et al. Importance of secondary screening with clinical isolates for anti-leishmania drug discovery. Sci Rep 2018;8:11765.
   PubMed Web of Science ®Google Scholar
• Lamotte S, Aulner N, Spath GF, Prina E. Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening. Sci Rep 2019;9:438.
   PubMed Web of Science ®Google Scholar
• Kipandula W, Young SA, MacNeill SA, Smith TK. Screening of the MMV and GSK open access chemical boxes using a viability assay developed against the kinetoplastid Crithidia fasciculata. Mol Biochem Parasitol 2018;222:61–9.
   PubMed Web of Science ®Google Scholar
• Ilari A, Genovese I, Fiorillo F, et al. Toward a drug against all kinetoplastids: from Leishbox to specific and potent trypanothione reductase inhibitors. Mol Pharm 2018;15:3069–78.
   PubMed Web of Science ®Google Scholar
• Salas-Sarduy E, Landaburu LU, Karpiak J, et al. Novel scaffolds for inhibition of cruzipain identified from high-throughput screening of anti-kinetoplastid chemical boxes. Sci Rep 2017;7:12073.
   PubMed Web of Science ®Google Scholar
• Salas-Sarduy E, Landaburu LU, Carmona AK, et al. Potent and selective inhibitors for M32 metallocarboxypeptidases identified from high-throughput screening of anti-kinetoplastid chemical boxes. PLoS Negl Trop Dis 2019;13:e0007560.
   PubMed Web of Science ®Google Scholar
• Charlton RL, Rossi-Bergmann B, Denny PW, Steel PG. Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art. Parasitology 2018;145:219–36.
   PubMed Web of Science ®Google Scholar
• Rodrigues IA, Mazotto AM, Cardoso V, Alves RL, et al. Natural products: insights into leishmaniasis inflammatory response. Mediat Inflamm 2015;2015:1.
   Web of Science ®Google Scholar
• Natarajan G, Oghumu S, Varikuti S, et al. Mechanisms of immunopathology of leishmaniasis. In: Satoskar A, Durvasula R, ed. Mechanisms of immunopathology of leishmaniasis. Pathogenesis of leishmaniasis: new developments in research. New York (NY): Springer-Verlag; 2013.
   Google Scholar